skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Lutetium Lu-177 Capromab (Code C67039)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lutetium Lu-177 Capromab

Definition: A radioimmunoconjugate consisting of capromab linked to lutetium Lu 177 via the bifunctional macrocyclic chelator methoxy-tetraazacyclododecane-tetraacetic acid (MeO-DOTA) with potential antineoplastic activity. Lutetium Lu 177-capromab binds to human prostate specific membrane antigen (PSMA) expressed on tumor cell surfaces via its capromab moiety and, upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA is a cell surface glycoprotein abundantly expressed by prostate epithelium and is typically overexpressed by prostate cancer cells.

Label: Lutetium Lu-177 Capromab

NCI Thesaurus Code: C67039 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1881486  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Lutetium Lu-177 Capromab
Lutetium Lu 177-Labeled Capromab

External Source Codes: 
PDQ Closed Trial Search ID 539702
PDQ Open Trial Search ID 539702 (check for NCI PDQ open clinical trial info)
UMLS CUI C1881486

Other Properties:
     Name Value (qualifiers indented underneath)
code C67039
Legacy_Concept_Name Lutetium_Lu_177_Monoclonal_Antibody_7E11
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom